SE400124B - Sett att framstella karcinoembryonalt antigen (cea) fran adenokarcinomvevnad - Google Patents

Sett att framstella karcinoembryonalt antigen (cea) fran adenokarcinomvevnad

Info

Publication number
SE400124B
SE400124B SE7106677A SE667771A SE400124B SE 400124 B SE400124 B SE 400124B SE 7106677 A SE7106677 A SE 7106677A SE 667771 A SE667771 A SE 667771A SE 400124 B SE400124 B SE 400124B
Authority
SE
Sweden
Prior art keywords
adenocarcinomic
carcino
cea
substance
preparing
Prior art date
Application number
SE7106677A
Other languages
English (en)
Swedish (sv)
Inventor
S O Freedman
P Gold
J H Krupey
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SE400124B publication Critical patent/SE400124B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/804—Radioisotope, e.g. radioimmunoassay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SE7106677A 1970-06-01 1971-05-24 Sett att framstella karcinoembryonalt antigen (cea) fran adenokarcinomvevnad SE400124B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3806970A 1970-06-01 1970-06-01

Publications (1)

Publication Number Publication Date
SE400124B true SE400124B (sv) 1978-03-13

Family

ID=21897920

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7106677A SE400124B (sv) 1970-06-01 1971-05-24 Sett att framstella karcinoembryonalt antigen (cea) fran adenokarcinomvevnad

Country Status (14)

Country Link
US (1) US3663684A (da)
JP (4) JPS5122047B1 (da)
BE (1) BE767800A (da)
CA (1) CA964580A (da)
CH (2) CH615439A5 (da)
DE (2) DE2065867B2 (da)
DK (1) DK144591C (da)
FR (1) FR2095728A5 (da)
GB (4) GB1321997A (da)
IL (2) IL34722A (da)
IT (1) IT995014B (da)
NL (2) NL7107501A (da)
SE (1) SE400124B (da)
ZA (1) ZA704069B (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867363A (en) * 1970-06-01 1975-02-18 Hans John Hansen Carcinoembryonic antigens
US4180499A (en) * 1971-01-27 1979-12-25 Hoffmann-La Roche Inc. Carcinoembryonic antigens
US3956258A (en) * 1972-05-12 1976-05-11 Hoffmann-La Roche Inc. Carcinoembryonic antigens
US3927193A (en) * 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US4022876A (en) * 1973-06-21 1977-05-10 Stanford Research Institute Mass spectrometric immunoassay
US4132769A (en) * 1974-10-30 1979-01-02 Osther Kurt B Cancer antigen, cancer therapy, and cancer diagnosis
DE2456224A1 (de) * 1974-11-28 1976-08-12 Karl Dr Med Theurer Verwendung von nativen antikoerpern oder von antikoerper-fragmenten mit kovalent gebundenen oder konjugierten zytostatisch und/bzw. oder zytotoxisch wirkenden substanzen fuer die krebstherapie
US3999944A (en) * 1975-02-28 1976-12-28 Hoffmann-La Roche Inc. Detection of breast cancer
US4043757A (en) * 1975-05-20 1977-08-23 Ortho Pharmaceutical Corporation Method for detection of human mammary carcinoma
US4152410A (en) * 1975-09-03 1979-05-01 Eisai Co., Ltd. Diagnosis reagent for neoplasm and method for diagnosis of neoplasm
US4086217A (en) * 1976-03-03 1978-04-25 Hoffmann-La Roche Inc. Carcinoembryonic antigens
US4132767A (en) * 1976-04-05 1979-01-02 Eisai Co., Ltd. Preparation of α-L antibody, purification of α-L antigen and reagent for detection of α-L antibody and α-L antigen
US4140753A (en) * 1976-04-30 1979-02-20 Scripps Clinic & Research Foundation Diagnostic method and reagent
US4145336A (en) * 1976-04-30 1979-03-20 Scripps Clinic And Research Foundation Carcinoembryonic antigen isomer
US4160817A (en) * 1976-09-29 1979-07-10 Research Corporation Application of protein-protein interaction as an assay for the detection of cancer
GB1598811A (en) * 1977-01-12 1981-09-23 Hoffmann La Roche Carcinoma-associated antigens
US4146603A (en) * 1977-02-18 1979-03-27 Research Corporation Tumor specific glycoproteins and method for detecting tumorigenic cancers
US4180556A (en) * 1977-03-09 1979-12-25 Abbott Laboratories Pretreatment method for carcinoembryonic antigen assay
JPS548714A (en) * 1977-06-16 1979-01-23 Saikin Kagaku Kenkiyuushiyo Kk Production of specific antiserum
US4234476A (en) * 1978-03-07 1980-11-18 Research Corporation Application of protein-protein interaction as an assay for the detection of cancer
US4241044A (en) * 1978-12-28 1980-12-23 Abbott Laboratories Method of diagnosing cancer by detecting elevated anti-T antibody activity
US4349528A (en) * 1979-11-21 1982-09-14 The Wistar Institute Monocolonal hybridoma antibody specific for high molecular weight carcinoembryonic antigen
US4299815A (en) * 1980-02-08 1981-11-10 Hoffmann-La Roche Inc. Carcinoembryonic antigen determination
US4317877A (en) * 1980-06-05 1982-03-02 Sloan Kettering Institute Process for detecting the presence of malignant and pre-malignant cells in humans
US4559311A (en) * 1981-08-27 1985-12-17 Stenman Ulf Hakan Diagnostic method using oncofetal peptide as a tumor marker
FR2520235A1 (fr) * 1982-01-27 1983-07-29 Bel Fromageries Procede de separation d'immunoglobulines a partir de colostrum
US4863853A (en) * 1982-04-21 1989-09-05 Bartos Patent Development And Holding Company Limited Method of determining the diagnostic value of monitoring serum-CEA-levels in a carcinoma patient undergoing therapy
DE3230299A1 (de) * 1982-08-14 1984-02-16 Hoechst Ag, 6230 Frankfurt Carcinoembryonales antigen, verfahren zu seiner isolierung und seine verwendung
DK557483A (da) * 1982-12-06 1984-06-07 Hoffmann La Roche Fremgangsmaade til bestemmelse af cea
US6013772A (en) * 1986-08-13 2000-01-11 Bayer Corporation Antibody preparations specifically binding to unique determinants of CEA antigens or fragments thereof and use of the antibody preparations in immunoassays
JPS63187697U (da) * 1987-05-26 1988-12-01
CA2116640A1 (en) * 1993-03-25 1994-09-26 Alexey Terskikh Carcinoembryonic antigen derivatives
US5705351A (en) * 1994-10-25 1998-01-06 Sahasrabudhe; Madhao B. Diagnosis of cancer using tumor-mimetic cell surface antigen from chemically modified normal cells
US5635361A (en) * 1994-10-25 1997-06-03 Sahasrabudhe; Madhao B. Diagnosis of cancer using tumor-mimetic cell surface antigen from chemically modified normal cells
EP1803814A1 (en) 2005-12-27 2007-07-04 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Method of improving the antibody selection capacity in phage-display library
JP7060510B2 (ja) * 2016-09-06 2022-04-26 富士レビオ株式会社 腫瘍マーカーの測定方法及び測定試薬

Also Published As

Publication number Publication date
IL34722A0 (en) 1970-08-19
IT995014B (it) 1975-11-10
DK144591C (da) 1982-09-20
JPS5617619B1 (da) 1981-04-23
JPS5122047B1 (da) 1976-07-07
IL34722A (en) 1974-03-14
DE2029499C3 (de) 1983-12-22
FR2095728A5 (da) 1972-02-11
GB1322000A (en) 1973-07-04
NL7801570A (nl) 1978-06-30
DE2029499B2 (de) 1976-10-28
CH615439A5 (da) 1980-01-31
CA964580A (en) 1975-03-18
JPS5327334B1 (da) 1978-08-08
US3663684A (en) 1972-05-16
CH611629A5 (da) 1979-06-15
ZA704069B (en) 1972-01-26
DK144591B (da) 1982-04-05
JPS5516267B1 (da) 1980-04-30
GB1321997A (en) 1973-07-04
BE767800A (fr) 1971-11-29
DE2029499A1 (de) 1971-12-16
NL7107501A (da) 1971-12-03
GB1321998A (en) 1973-07-04
DE2065867B2 (de) 1980-06-04
GB1321999A (en) 1973-07-04
DE2065867A1 (de) 1976-09-16
IL42508A0 (en) 1973-08-29

Similar Documents

Publication Publication Date Title
SE400124B (sv) Sett att framstella karcinoembryonalt antigen (cea) fran adenokarcinomvevnad
FI53940C (fi) Foerfarande och anordning foer framstaellning av en polymerskumstroem
BG19802A3 (bg) Метод за получаване на фенил-имидазолилалканилови производни
BG20582A3 (bg) Метод за получаване на р-халоген-фенил-2-пиромидинони
ZA716710B (en) Extraction of protein from seed
DK132659C (da) Fremgangsmade til fremstilling af alkyl-cis-chrysanthemater
DK143965C (da) Fremgangsmaade til fremstilling af adskilte phosphatider
SE382227B (sv) Forfarande for separering av amylos.
BG19133A3 (bg) Метод за получаване на 1-фенил-2-хидрокси-3-хидроксилалкиламинопропани
SE373572B (sv) Forfarande for framstellning av pyroglutamyl-histidyl-prolinamid
BG18601A3 (bg) Метод за получаване на фениламиноалкани
DK124130B (da) Fremgangsmåde til fremstilling af ren hexetidin.
BG20585A3 (bg) Метод за получаване на заместени n-хидрокси-алкил-2-ариламино-имидазолини
DK129450B (da) Fremgangsmåde til ætinylering af 17-ketosteroider.
SE382320B (sv) Forfarande for framstellning av diamanter
SE382051B (sv) Forfarande for framstellning av 3-sulfonamid-4-hydroxifenyl-2-piperidylkarbinoler
IT939178B (it) Procedimento per la preparazione di alogenuri glicidiltrialchilam monici
IT983093B (it) Metodo per preparare capsule minuscole
SU464113A3 (ru) Способ получени тетрагидробензодиазепинонов
DK131786B (da) Fremgangsmåde til fremstilling af delta4-3-oxo-1alfa-methylsteroider.
SE395726B (sv) Sett och anordning for framstellning av ett tradarmerat sammansatt material
DK137006B (da) Fremgangsmåde til fremstilling af 1-chlor-3-methyl-2-buten.
SE392874B (sv) Forfarande for utmatning av med vetskor behandlade fasta emnen fran vertikala kolonner
RO76229A (ro) Procedeu pentru prepararea n-izopropilanilinei
BG17979A3 (bg) Метод за получаване на дез- фенила- ланин в1- инсулин